President Donald Trump signed an executive order accelerating access to psychedelic-assisted treatments for Americans suffering from serious mental illness, with a specific focus on veterans. The directive instructs the FDA, HHS, DEA, and VA to fast-track research and regulatory review of drugs like ibogaine for PTSD, depression, substance abuse, and suicide prevention. The order includes $50 million in state matching funds to support these initiatives.
While the order is domestically focused, Trump's recent statements on military posture have raised questions about foreign policy priorities. Prediction markets currently place a 6.5% probability on a US declaration of war with Iran by December 31, 2026, down from 8% a week ago. Analysts view the executive order as having low direct impact on geopolitical risk assessments.